TCM Biotech International (4169) Stock Overview
A biotech company, engages in the research and development of drugs for liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for 4169 from our risk checks.
4169 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
TCM Biotech International Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$234.00 |
| 52 Week High | NT$250.00 |
| 52 Week Low | NT$43.65 |
| Beta | 0.037 |
| 1 Month Change | 28.57% |
| 3 Month Change | 30.73% |
| 1 Year Change | 302.06% |
| 3 Year Change | 377.55% |
| 5 Year Change | 688.11% |
| Change since IPO | 716.14% |
Recent News & Updates
Recent updates
Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?
Jan 31
Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend
Jan 04We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt
Dec 07
Shareholder Returns
| 4169 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 19.4% | -3.9% | -4.8% |
| 1Y | 302.1% | 10.2% | 45.7% |
Return vs Industry: 4169 exceeded the TW Biotechs industry which returned 10.2% over the past year.
Return vs Market: 4169 exceeded the TW Market which returned 45.7% over the past year.
Price Volatility
| 4169 volatility | |
|---|---|
| 4169 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in TW Market | 9.7% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4169 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4169's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Ya-Chun Wang | www.tcmbio.com |
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories.
TCM Biotech International Corp. Fundamentals Summary
| 4169 fundamental statistics | |
|---|---|
| Market cap | NT$14.20b |
| Earnings (TTM) | NT$21.08m |
| Revenue (TTM) | NT$682.40m |
Is 4169 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4169 income statement (TTM) | |
|---|---|
| Revenue | NT$682.40m |
| Cost of Revenue | NT$361.66m |
| Gross Profit | NT$320.74m |
| Other Expenses | NT$299.66m |
| Earnings | NT$21.08m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 47.00% |
| Net Profit Margin | 3.09% |
| Debt/Equity Ratio | 2.7% |
How did 4169 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 09:01 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TCM Biotech International Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |